Clinical trial registry record

4D-150 in Patients With Neovascular (Wet) Age-Related Macular Degeneration

A registered PHASE1, PHASE2 study indexed because it matched monitored longevity research terms. Registry status: Recruiting. Registration does not establish safety or effectiveness.

Plain-language guide

Five questions to ask about this record

What this is
A clinical study registration, not a result or recommendation.
Why it may matter
The registry currently reports Recruiting.
Evidence
Registered phase 1, phase 2 study.
Main limitation
Registration does not prove that the intervention works, is safe, or is available to you.
What changed
Registry metadata was last updated August 21, 2026.
Where to verify
Open the primary registry below for eligibility, locations, contacts, and current status.
Registry ID
NCT05197270
Last registry update
August 21, 2026
Status
Recruiting
Phase
Phase 1, Phase 2
Sponsor
4D Molecular Therapeutics
Enrollment
215
Countries
United States, Puerto Rico
Match confidence
100%
Source feed
ClinicalTrials.gov
Automated source synopsis

A registered PHASE1, PHASE2 study indexed because it matched monitored longevity research terms. Registry status: Recruiting. Registration does not establish safety or effectiveness.

Evidence snapshot

What the source actually supports

Evidence stage
Phase 1, Phase 2
Study design
RANDOMIZED · SEQUENTIAL · TREATMENT · SINGLE
Evidence population
Human clinical study registration
Participants
215
Population
ALL · 50 Years
Duration
2021-12-09 to 2031-01-01
Intervention
4D-150 IVT; Aflibercept IVT
Comparator
4D-150 Dose Expansion Control
Outcomes measured
Incidence and severity of treatment emergent adverse events (TEAEs) and serious adverse events (SAEs), including clinic…; Time to receiving the first supplemental aflibercept injection — 52 weeks; Percentage of subjects requiring supplemental aflibercept injections over 52 weeks — 52 weeks; Number of supplemental aflibercept injections over 52 weeks — 52 weeks; Change from baseline in BCVA over time (up to 52 weeks) as assessed using the ETDRS Visual Acuity Chart — 52 weeks; Change from baseline in central subfield thickness (CST) over time (up to 52 weeks) measured by spectral domain optical…; Percent Change in Annualized Mean Number of anti-VEGF IVT injections before and after the 4D-150 injection — Before and…
Reported result
No reusable finding-level result is available in this record.

Main limitationThis is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.

Safety and approvalEligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians. Trial registration is not regulatory approval and does not establish that an intervention is available.

Source supportStructured registry protocol metadata; no finding-level conclusion is generated.

Trial stage · Phase 1, Phase 2A trial phase describes development stage; it does not establish a positive result.
Phase 1Phase 2Phase 3Phase 4

Registration and recruitment status do not establish safety, efficacy, or regulatory approval.

Why this record appears here · 100% topic match

The title, summary, or source keywords matched one or more topics followed by immortal.life. A higher percentage means a stronger topic match; it does not rate safety, effectiveness, or study quality.

  • Vision ageing · 100%Title contains controlled term: age-related macular degeneration. Source terminology contains: age-related macular degeneration. Title supplies longevity context: age-related. Study type is explicitly identified as INTERVENTIONAL.

Automated source check 100% · update recency 100%. These figures help sort records; they are not medical ratings.

vision aging
Open primary sourceExport JSON